Files and links (1)
Published, Version of Record (VoR)CC BY-NC-ND V4.0, Open
Journal article
Autologous stem cell transplantation for acute myeloid leukemia in first remission
Biology of blood and marrow transplantation, v 6(1)
2000
PMID: 10707999
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
We studied the feasibility, toxicity, and efficacy of a 2-step approach to autologous stem cell transplantation for patients with acute myeloid leukemia in first remission. Step 1 consisted of consolidation chemotherapy including cytarabine 2000 mg/m2 twice daily for 4 days concurrent with etoposide 40 mg/kg by continuous infusion over 4 days. During the recovery from this chemotherapy, peripheral blood stem cells were collected under granulocyte colony-stimulating factor stimulation. Step 2, autologous stem cell transplantation, involved the preparative regimen of busulfan 16 mg/kg followed by etoposide 60 mg/kg and reinfusion of unpurged peripheral blood stem cells. A total of 128 patients were treated. During step 1, there was 1 treatment-related death. A median CD34+ cell dose of 14 (x10(6)/kg) was collected in 3 aphereses. Ten patients suffered relapse before transplantation, and 117 patients (91%) proceeded to transplantation. During step 2, there were 2 treatment-related deaths, and 35 patients subsequently suffered relapse. With median follow-up of 30 months, 5-year disease-free survival for all patients entered in the study is projected to be 55%. By cytogenetic risk group, 5-year disease-free survival is 73% for favorable-risk patients, 51% for intermediate-risk patients, and 0% for poor-risk patients. We conclude that this 2-step approach to autologous transplantation produces excellent stem cell yields and allows a high percentage of patients to receive the intended therapy. Preliminary efficacy analysis is very encouraging, with outcomes that appear superior to those of conventional chemotherapy.
Biol Blood Marrow Transplant 2000;6(1):50-7.
Metrics
Details
- Title
- Autologous stem cell transplantation for acute myeloid leukemia in first remission
- Creators
- Charles A. Linker - University of California, San FranciscoCurt A. Ries - University of California, San FranciscoLloyd E. Damon - University of California, San FranciscoPeter Sayre - University of California, San FranciscoWillis Navarro - University of California, San FranciscoHope S. Rugo - University of California, San FranciscoArnold Rubin - University of California, San FranciscoDelvyn Case - University of California, San FranciscoPamela Crilley - University of California, San FranciscoDavid Topolsky - University of California, San FranciscoIsadore Brodsky - University of California, San FranciscoKen Zamkoff - University of California, San FranciscoJeffrey L. Wolf - University of California, San FranciscoAdelle Shalit Rubin - [Retired Faculty]
- Publication Details
- Biology of blood and marrow transplantation, v 6(1)
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- [Retired Faculty]
- Web of Science ID
- WOS:000090022000006
- Scopus ID
- 2-s2.0-0033629775
- Other Identifier
- 991019168693504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Hematology
- Immunology
- Transplantation